GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Marpai Inc (NAS:MRAI) » Definitions » Sloan Ratio %

Marpai (Marpai) Sloan Ratio % : -44.29% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Marpai Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Marpai's Sloan Ratio for the quarter that ended in Dec. 2023 was -44.29%.

Warning Sign:

When sloan ratio (-44.29)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Dec. 2023, Marpai has a Sloan Ratio of -44.29%, indicating earnings are more likely to be made up of accruals.


Marpai Sloan Ratio % Historical Data

The historical data trend for Marpai's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marpai Sloan Ratio % Chart

Marpai Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
- -20.90 -33.56 -47.35 -44.29

Marpai Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.35 -57.59 -68.50 -85.27 -44.29

Competitive Comparison of Marpai's Sloan Ratio %

For the Healthcare Plans subindustry, Marpai's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marpai's Sloan Ratio % Distribution in the Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, Marpai's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Marpai's Sloan Ratio % falls into.



Marpai Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Marpai's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-28.752--15.749
-1.027)/31.679
=-44.29%

Marpai's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-28.752--15.749
-1.027)/31.679
=-44.29%

Marpai's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -8.873 (Mar. 2023 ) + -7.557 (Jun. 2023 ) + -7.295 (Sep. 2023 ) + -5.027 (Dec. 2023 ) = $-28.75 Mil.
Marpai's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -6.54 (Mar. 2023 ) + -2.199 (Jun. 2023 ) + -6.585 (Sep. 2023 ) + -0.425 (Dec. 2023 ) = $-15.75 Mil.
Marpai's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 0.003 (Mar. 2023 ) + 0.015 (Jun. 2023 ) + 0.009 (Sep. 2023 ) + 1 (Dec. 2023 ) = $1.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marpai  (NAS:MRAI) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Marpai has a Sloan Ratio of -44.29%, indicating earnings are more likely to be made up of accruals.


Marpai Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Marpai's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Marpai (Marpai) Business Description

Traded in Other Exchanges
N/A
Address
5701 East Hillsborough Avenue, Suite 1417, Tampa, FL, USA, 33610-5428
Marpai Inc operates as a health plan company. It uses A.I. to predict and help prevent costly events for its members, and in turn, lower its clients' health care costs. It offers a health plan services system that addresses the problems of healthcare past and enables companies to provide healthcare to employees. The company generates the majority of its revenue from the United States.
Executives
Yaron Eitan director 65 CHALLENGER ROAD, RIDGEFIELD PARK NJ 07660
Damien Lamendola director, 10 percent owner 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Edmundo Gonzalez director, officer: CEO, Secretary and Director C/O SELWAY CAPITAL ACQUISITION CORP., 74 GRAND AVENUE, 2ND FLOOR, ENGLEWOOD NJ 07631
Sagiv Shiv director
Vincent Kane director 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33131
Ronnie Brown officer: Chief Operating Officer 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Mohsen Moazami director C/O ASTREA ACQUISITION CORP., 55 OCEAN LANE DRIVE, APT. 3021, KEY BISCAYNE FL 33149
Lutz Finger officer: See Remarks 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610
Yoram Bibring officer: Chief Financial Officer C/O SELWAY ACQUISITION CORPORATION, 66 FORD ROAD, SUITE 230, DENVILLE NJ 07834
Jane Cavalier director 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Diclaudio Colleen director 456 SEATON STREET, LOS ANGELES CA 90013
Art Hoath officer: Chief Revenue Officer 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Gonen Antebi director 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Eli David other: See footnote (1) 5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33131